CJC-1295 + IPA

This product is a lyophilized blend combining two distinct peptide compounds: CJC-1295 (without Drug Affinity Complex) and Ipamorelin. This combination is widely utilized in research settings to investigate synergistic pathways influencing growth hormone (GH) secretion. CJC-1295 (modified GRF 1-29) is a synthetic analogue of growth hormone-releasing hormone (GHRH). The “without DAC” form has a shorter…

Description

Research & Mechanisms

1. Synergistic GH Release The primary research interest in this blend lies in its potential synergistic effect. Studies suggest that combining a GHRH analogue (CJC-1295) with a ghrelin receptor agonist (Ipamorelin) may lead to a more pronounced release of growth hormone compared to the administration of either peptide alone. This is often measured via downstream increases in Insulin-like Growth Factor 1 (IGF-1) levels in animal models.

2. Metabolic and Body Composition Research Researchers investigate this combination for its potential influence on energy metabolism, lipolysis (fat breakdown), and muscle protein synthesis. The blend is frequently used in studies focused on altering body composition markers and improving metabolic efficiency in rodent models.

3. Cellular Repair and Anti-Aging Models Given the role of the GH/IGF-1 axis in tissue maintenance, this blend is a subject of interest in research related to cellular repair mechanisms, wound healing acceleration, and the study of age-related decline in hormonal signaling.